Tarek Haj Shehadeh

Tarek Haj Shehadeh

Auto-generated profile, based on publicly available information

Tarek Haj Shehadeh

Department of Orthopedics and Rehabilitation, Penn State Health, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2025 in Injury
Verified
Journal Article
Open access
Daniel Enrique PereiraDaniel Enrique Pereira
Daniel Enrique Pereira
ZSZina Smadi
Zina Smadi
AMAudrey Millar
Audrey Millar
TSTarek Haj Shehadeh
Tarek Haj Shehadeh
AAAmir Alsaidi
Amir Alsaidi
JSJason Strelzow
Jason Strelzow
Malnutrition has emerged as a significant risk factor for postoperative complications in orthopaedic surgery. Despite this, the impact of malnutrition in orthopaedic trauma remains underexplored. This study aims to investigate 90 day and 1 year postoperative outcomes of ankle and pilon fracture open reduction and internal fixation (ORIF) in malnourished patients. Using a national database, adult patients who underwent surgery for ankle or pilon fractures with a minimum of one-year follow-up were identified. Patients were stratified into two cohorts based on the presence of serum markers for malnutrition within the year preceding surgery. Malnutrition was identified by any of the following values: serum or plasma transferrin ≤204 mg/dL, blood leukocytes ≤1.5 × 10³/µL, or albumin ≤3.5 g/dL. A 1:1 propensity score matching was performed with matched controls for relevant risk factors, demographics and comorbidities. Before matching, 80,761 ankle fracture patients (7,455 malnourished; 73,306 controls) and 14,258 pilon fracture patients (1,648 malnourished; 12,610 controls) were identified. After matching, 14,676 ankle fracture (mean age 58.4 ± 16.9 years) and 3,214 pilon fracture (mean age 50.1 ± 17.2 years) patients were included. In the ankle fracture analysis, malnourished patients had higher rates of wound complications, post-operative infection, anemia, blood transfusions, incision and drainage and implant removal at 90 days post-operatively (p<0.0001). Within one year, malnutrition was significantly associated with increased malunion, non-union, amputation and implant related complications such infections, implant removal and irritation and debridement (p<0.05). Comparisons for pilon fracture patients were the same in addition to higher rates of wound complications (p<0.001) in malnourished patients. Patients with malnutrition undergoing surgical fixation for ankle and pilon fractures experienced significantly higher rates of systemic complications and adverse surgical outcomes including infections, nonunion and all-cause return to the OR for staged removal of hardware, debridements, arthrodesis, and amputation. These findings should direct postoperative risk management and motivate study into interventions aimed at promoting nutrition and preventing complications in this at-risk population.

16 April 2026 in European Journal of Orthopaedic Surgery & Traumatology
Verified
Journal Article
Closed access
TSTarek Haj Shehadeh
Tarek Haj Shehadeh
JAJoseph Abboud
Joseph Abboud

21 April 2026 in Journal of the American Academy of Orthopaedic Surgeons
Verified
Journal Article
Closed access
TSTarek Haj Shehadeh
Tarek Haj Shehadeh
PBPeter Boufadel
Peter Boufadel
JAJoseph A. Abboud
Joseph A. Abboud
Introduction: Total shoulder arthroplasty (TSA) is being performed with increasing frequency and is projected to rise further in the coming years. Although generally successful, the procedure carries inherent risks. Diabetes is a well-established risk factor for postoperative complications. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are effective antidiabetic agents that are widely used; however, their perioperative safety in the setting of TSA has not yet been evaluated. The objective of this study was to assess the effect of perioperative SGLT2i use on 90-day medical complications and 2-year implant-related complications in diabetic patients undergoing TSA. Methods: The TriNetX database was queried to identify diabetic patients who underwent TSA. Patients were stratified according to SGLT2i prescription status, and 1:1 propensity score matching was done to adjust for relevant demographic and medical comorbidities. Outcomes of interest included 90-day medical and surgical complications and 2-year implant-related complications. Results: After propensity score matching, each cohort included 2,360 patients. The SGLT2i cohort demonstrated a significantly higher 90-day risk of myocardial infarction compared with control subjects (2.03% vs 0.89%, P = 0.001). No significant differences were observed between groups in the 90-day risk of ketoacidosis, deep vein thrombosis, pulmonary embolism, stroke, pneumonia, acute kidney injury, transfusion, wound disruption, sepsis, or hospital readmission. Similarly, there was no increased risk of implant-related complications at 2 years postoperatively in the SGLT2i cohort. Discussion: SGLT2i use was associated with an increased 90-day risk of myocardial infarction after TSA but appeared safe regarding implant-related outcomes. Additional research is warranted to clarify these associations; however, these findings may aid in preoperative counseling and optimization of surgical outcomes. Level of Evidence: III

5 August 2025 in JSES Reviews, Reports, and Techniques
Verified
Journal Article
Open access
TSTarek Haj Shehadeh
Tarek Haj Shehadeh
JCJawaad Chaudhry
Jawaad Chaudhry
AAAhmed Abdeen
Ahmed Abdeen
GUGary Updegrove
Gary Updegrove
AAApril Armstrong
April Armstrong
NLNathan Lanham
Nathan Lanham
Metformin is an antidiabetic medication that is routinely prescribed. Recent reports suggest a dose-response disease-modifying effect on osteoarthritis (OA) of the knee with patients on metformin having a lower incidence of total knee arthroplasty. However, it is unknown whether this effect translates to OA of the shoulder. Therefore, the purpose of this study is to investigate the effect of metformin on the likelihood of having shoulder arthroplasty in patients with shoulder OA. The TriNetX database was used to identify a cohort of patients with shoulder OA. Two groups were formed. The first group was comprised of patients who were not prescribed metformin. The second group was comprised of patients who were prescribed metformin. Propensity score matching was performed to control for multiple cofounding variables including hemoglobin A1C levels. Both matched cohorts consisted of 26,327 patients each. The outcomes of interest were the incidence of shoulder arthroplasty up to 10 years after the diagnosis of shoulder OA, as well as serum inflammatory marker levels (C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and Cortisol). A total of 1,245 (4.729% risk) patients in the metformin group underwent shoulder arthroplasty compared to 962 (3.654% risk) patients in the nonmetformin group. The metformin group had averages of 30.703 mg/L ± 57.155 mg/L for CRP, 33.692 mm/hour ± 27.857 mm/hour for ESR and 13.224 μg/dL ± 8.450 μg/dL for cortisol. The nonmetformin group had averages of 36.577 mg/L ± 60.627 mg/L for CRP, 5.574 mm/hour ± 29.719 mm/hour for ESR and 13.326 μg/dL ± 8.571 μg/dL for cortisol. The metformin group had a significantly increased risk of arthroplasty of 1.075% [95% confidence interval (0.733%, 1.417%), P < .0001 and odds ratio = 1.309 [95% confidence interval (1.201-1.426)] compared to the nonmetformin group and had a longer follow-up period (P < .0001). Mean ESR and CRP inflammatory markers levels in the metformin group were significantly lower than the nonmetformin group (both P < .0001) However, there was a nonsignificant decrease in average cortisol levels (P = .779) in the metformin group when compared to the nonmetformin group. Patients with shoulder OA who are prescribed metformin are more likely to undergo shoulder arthroplasty than those not taking metformin, despite having significant decreases in inflammatory marker levels. These findings stand in contrast to previous data which suggest a potential dose-response disease-modifying effect on OA of the knee. Additional research is needed to better elucidate the mechanisms of metformin on OA.

23 March 2026 in Journal of Orthopaedics
Verified
Journal Article
Closed access
TSTarek Haj Shehadeh
Tarek Haj Shehadeh
JCJawaad Chaudhry
Jawaad Chaudhry
RSRicha Sandeep
Richa Sandeep
GUGary Updegrove
Gary Updegrove
AAApril Armstrong
April Armstrong
NLNathan Lanham
Nathan Lanham

12 August 2025 in JSES Reviews, Reports, and Techniques
Verified
Journal Article
Open access
TSTarek Haj Shehadeh
Tarek Haj Shehadeh
AAAhmed Abdeen
Ahmed Abdeen
NLNathan S. Lanham
Nathan S. Lanham
GUGary F. Updegrove
Gary F. Updegrove
Platelet-rich plasma (PRP) is used for a variety of orthopedic conditions with varying degrees of efficacy. PRP has been shown to be most effective in the management of adhesive capsulitis and lateral epicondylitis. However, preparation methods, dosing and frequency of PRP injections vary widely among published studies. Further research is needed to better clarify which preparations and orthopedic conditions are best for PRP treatment.